Ioannis Roxanis

1.6k total citations
18 papers, 553 citations indexed

About

Ioannis Roxanis is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Ioannis Roxanis has authored 18 papers receiving a total of 553 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 6 papers in Molecular Biology and 6 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Ioannis Roxanis's work include HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cancer Genomics and Diagnostics (4 papers). Ioannis Roxanis is often cited by papers focused on HER2/EGFR in Cancer Research (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Cancer Genomics and Diagnostics (4 papers). Ioannis Roxanis collaborates with scholars based in United Kingdom, United States and Italy. Ioannis Roxanis's co-authors include Anthony Kong, Merel Gijsen, Adrian L. Harris, Jiliang Li, Jacek Capala, Gabriela Krämer-Marek, David J. Barry, Robert P. Jenkins, Erik Sahai and Maeve Mullooly and has published in prestigious journals such as Journal of Clinical Investigation, Nature Communications and Cancer Research.

In The Last Decade

Ioannis Roxanis

17 papers receiving 547 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ioannis Roxanis United Kingdom 10 306 187 172 88 74 18 553
Véronique Garambois France 15 306 1.0× 296 1.6× 274 1.6× 162 1.8× 77 1.0× 32 775
George S. Laszlo United States 15 401 1.3× 435 2.3× 93 0.5× 48 0.5× 208 2.8× 35 814
Hoiseon Jeong South Korea 11 295 1.0× 192 1.0× 61 0.4× 90 1.0× 115 1.6× 24 552
M. Bennett United Kingdom 3 295 1.0× 218 1.2× 107 0.6× 113 1.3× 31 0.4× 5 590
Joachim Wahl Germany 14 334 1.1× 186 1.0× 176 1.0× 41 0.5× 157 2.1× 28 531
Bruce D. Cohen United States 10 322 1.1× 420 2.2× 154 0.9× 102 1.2× 57 0.8× 12 810
Anna Laura Aloisi Italy 6 317 1.0× 177 0.9× 97 0.6× 87 1.0× 26 0.4× 6 481
Frank Herting Switzerland 13 232 0.8× 318 1.7× 196 1.1× 65 0.7× 165 2.2× 28 712
Nicholas Murray United Kingdom 10 168 0.5× 224 1.2× 56 0.3× 94 1.1× 68 0.9× 19 669
Jinming Gu United States 5 214 0.7× 217 1.2× 222 1.3× 51 0.6× 48 0.6× 5 422

Countries citing papers authored by Ioannis Roxanis

Since Specialization
Citations

This map shows the geographic impact of Ioannis Roxanis's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ioannis Roxanis with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ioannis Roxanis more than expected).

Fields of papers citing papers by Ioannis Roxanis

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ioannis Roxanis. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ioannis Roxanis. The network helps show where Ioannis Roxanis may publish in the future.

Co-authorship network of co-authors of Ioannis Roxanis

This figure shows the co-authorship network connecting the top 25 collaborators of Ioannis Roxanis. A scholar is included among the top collaborators of Ioannis Roxanis based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ioannis Roxanis. Ioannis Roxanis is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

18 of 18 papers shown
1.
Zhang, Yu, Ioanna Mavrommati, Chris Starling, et al.. (2024). Abstract PO4-13-11: Epigenetically defined sub-clonal heterogeneity drives therapy resistance in triple-negative breast cancer. Cancer Research. 84(9_Supplement). PO4–13. 1 indexed citations
2.
Provenzano, Elena, Sara Lightowlers, Selvakumar Anbalagan, et al.. (2024). Longitudinal Assessment of Tumor-Infiltrating Lymphocytes in Primary Breast Cancer Following Neoadjuvant Radiation Therapy. International Journal of Radiation Oncology*Biology*Physics. 120(3). 862–874. 3 indexed citations
3.
4.
Fitzpatrick, Amanda, Marjan Iravani, David Vicente, et al.. (2023). Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype. Nature Communications. 14(1). 7408–7408. 9 indexed citations
5.
Tovey, Holly, Joel S. Parker, Katherine A. Hoadley, et al.. (2023). Integrated Multimodal Analyses of DNA Damage Response and Immune Markers as Predictors of Response in Metastatic Triple-Negative Breast Cancer in the TNT Trial (NCT00532727). Clinical Cancer Research. 29(18). 3691–3705. 3 indexed citations
6.
Graham, Rosalind, Patrycja Gazińska, Atousa Khiabany, et al.. (2023). Serum-derived extracellular vesicles from breast cancer patients contribute to differential regulation of T-cell-mediated immune-escape mechanisms in breast cancer subtypes. Frontiers in Immunology. 14. 1204224–1204224. 22 indexed citations
7.
Fotiadis, Nicos, et al.. (2023). Next-Generation Sequencing and Image-Guided Tissue Sampling: A Primer for Interventional Radiologists. Journal of Vascular and Interventional Radiology. 34(8). 1291–1302.e1. 4 indexed citations
8.
Alexander, John, Odette Mariani, Laetitia Fuhrmann, et al.. (2022). Assessment of the Molecular Heterogeneity of E-Cadherin Expression in Invasive Lobular Breast Cancer. Cancers. 14(2). 295–295. 9 indexed citations
9.
Sheldon, Helen, Esther Bridges, Ildefonso Silva, et al.. (2021). ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression. Molecular Cancer Research. 19(11). 1957–1969. 7 indexed citations
10.
Park, Danielle, David J. Barry, Robert P. Jenkins, et al.. (2021). A FIJI macro for quantifying pattern in extracellular matrix. Life Science Alliance. 4(3). e202000880–e202000880. 86 indexed citations
11.
Smith, Henry, Jasbani H.S. Dayal, Tencho Tenev, et al.. (2020). RIPK1‐mediated immunogenic cell death promotes anti‐tumour immunity against soft‐tissue sarcoma. EMBO Molecular Medicine. 12(6). e10979–e10979. 26 indexed citations
12.
Roxanis, Ioannis, Helen Sheldon, Francesca M. Buffa, et al.. (2015). Combining lapatinib and pertuzumab to overcome lapatinib resistance due to NRG1-mediated signalling in HER2-amplified breast cancer. Oncotarget. 6(8). 5678–5694. 31 indexed citations
13.
Generali, Daniele, Gabriela Krämer-Marek, Merel Gijsen, et al.. (2014). ADAM10 mediates trastuzumab resistance and is correlated with survival in HER2 positive breast cancer. Oncotarget. 5(16). 6633–6646. 68 indexed citations
14.
Generali, Daniele, Gabriela Krämer-Marek, Merel Gijsen, et al.. (2014). Nuclear HER4 mediates acquired resistance to trastuzumab and is associated with poor outcome in HER2 positive breast cancer. Oncotarget. 5(15). 5934–5949. 50 indexed citations
15.
Canonici, Alexandra, Merel Gijsen, Maeve Mullooly, et al.. (2013). Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer. Oncotarget. 4(10). 1592–1605. 137 indexed citations
16.
Krämer-Marek, Gabriela, Merel Gijsen, Dale O. Kiesewetter, et al.. (2012). Potential of PET to Predict the Response to Trastuzumab Treatment in an ErbB2-Positive Human Xenograft Tumor Model. Journal of Nuclear Medicine. 53(4). 629–637. 30 indexed citations
17.
Roxanis, Ioannis & J.W.M. Chow. (2010). Cellular cohesion as a prognostic factor in malignant melanoma: a retrospective study with up to 12 years follow-up. Modern Pathology. 23(4). 502–510. 3 indexed citations
18.
Moody, Anne Marie, Paul Moss, Ioannis Roxanis, et al.. (1998). A pathogenetic role for the thymoma in myasthenia gravis. Autosensitization of IL-4- producing T cell clones recognizing extracellular acetylcholine receptor epitopes presented by minority class II isotypes.. Journal of Clinical Investigation. 101(10). 2268–2277. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Véronique Garambois Breakdown of academic impact, for papers by George S. Laszlo Breakdown of academic impact, for papers by Hoiseon Jeong Breakdown of academic impact, for papers by M. Bennett Breakdown of academic impact, for papers by Joachim Wahl Breakdown of academic impact, for papers by Bruce D. Cohen Breakdown of academic impact, for papers by Anna Laura Aloisi Breakdown of academic impact, for papers by Frank Herting Breakdown of academic impact, for papers by Nicholas Murray Breakdown of academic impact, for papers by Jinming Gu
Rankless by CCL
2026